Evidence map›Paper›PMID 12368209›Full record

ArticleThe American journal of pathology2002

Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.

Hyangkyu Lee, David S Park, Babak Razani, Robert G Russell, Richard G Pestell, Michael P Lisanti

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 188 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Caveolin and NOS in the Development of Muscular Dystrophy.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Emerging Role of Caveolin-1 in GLP-1 Action.Frontiers in endocrinology · 2021
    Review
  14. A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies.International journal of molecular sciences · 2020
    Review
  15. Review
  16. Energy and Dynamics of Caveolae Trafficking.Frontiers in cell and developmental biology · 2020
    Review
  17. Role of Caveolin-1 in Diabetes and Its Complications.Oxidative medicine and cellular longevity · 2020
    Review
  18. Article
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Hyangkyu LeeDepartment of Molecular Pharmacology, Division of Hormone-Dependent Tumor Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
David S Park
Babak Razani
Robert G Russell
Richard G Pestell
Michael P Lisanti
Albert Einstein College of Medicine · USInstitute of Animal Sciences · CN

Funding

Initiation and Maintenance In Mammary TumorigenesisR01CA075503 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 1998 to 2011
$4.6M
TRAINING IN HORMONE-MEMBRANE INTERACTIONST32DK007513 · NIDDK · YESHIVA UNIVERSITY · PI ZUKIN, R. SUZANNE · 1986 to 2011
$3.7M
CYCLIN D1 FUNCTION IN PROSTATE CANCERR01CA086072 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2001 to 2013
$3.3M
CYTOSKELETAL ORGANIZATION AND MALIGNANT TRANSFORMATIONT32CA009475 · NCI · YESHIVA UNIVERSITY · PI SATIR, PETER · 1985 to 2002
$621k
ANTIPROGESTINS AND ACTIVE CELL DEATH IN BREAST CANCERR01CA070897 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI EL ETREBY, M F · 1998 to 2001
$250k
NCI NIH HHS R01 CA075503NCI NIH HHS R01 CA086072NCI NIH HHS R01-CA70897NCI NIH HHS R01-CA75503NCI NIH HHS R01-CA86072NCI NIH HHS T32 CA009475NCI NIH HHS TG-CA09475NIDDK NIH HHS T32 DK007513NIDDK NIH HHS T32-DK07513
6 · The paper itself

Abstract

Caveolin-1 (Cav-1) is the principal structural protein of caveolae membranes that are found in most cells types, including mammary epithelial cells. Recently, we mapped the human CAV1 gene to a suspected tumor suppressor locus (7q31.1/D7S522) that is deleted in a variety of human cancers, as well as mammary tumors. In addition, the CAV1 gene is mutated (P132L) in up to approximately 16% of human breast cancers. The mechanism by which deletion or mutation of the Cav-1 gene contributes to mammary tumorigenesis remains unknown. To understand the role of the Cav-1 (P132L) mutation in the pathogenesis of human breast cancers, we generated the same mutation in wild-type (WT) Cav-1 and studied its behavior in cultured cells. Interestingly, the P132L mutation leads to formation of misfolded Cav-1 oligomers that are retained within the Golgi complex and are not targeted to caveolae or the plasma membrane. To examine whether the Cav-1 (P132L) mutant behaves in a dominant-negative manner, we next co-transfected cells with Cav-1 (P132L) and WT Cav-1, and evaluated their caveolar targeting. Our results indicate that Cav-1 (P132L) behaves in a dominant-negative manner, causing the mislocalization and intracellular retention of WT Cav-1. Virtually identical results were obtained when Cav-1 (P132L) was stably expressed at physiological levels in a nontransformed human mammary epithelial cell line (hTERT-HME1). These data provide a molecular explanation for why only a single mutated CAV1 allele is found in patients with breast cancer. Thus, we next investigated if functional inactivation of Cav-1 gene expression leads to mammary tumorigenesis in vivo. For this purpose, we performed mammary gland analysis on Cav-1-deficient mice (-/-) that harbor a targeted disruption of the Cav-1 gene (a null mutation). Interestingly, we show that inactivation of Cav-1 gene expression leads to mammary epithelial cell hyperplasia, even in 6-week-old virgin female mice. These data clearly implicate loss of functional Cav-1 in the pathogenesis of mammary epithelial cell hyperplasia, and suggest that Cav-1-null mice represent a novel animal model to study premalignant mammary disease.

Indexed as

Gene DeletionPoint MutationAnimalsBreast NeoplasmsCaveolin 1CaveolinsChlorocebus aethiopsChromosome MappingChromosomes, Human, Pair 7COS CellsEpithelial CellsFemaleGenes, Tumor SuppressorHumansHyperplasiaMammary Glands, AnimalCAV1 protein, humanCav1 protein, mouseCaveolin 1CaveolinsRecombinant Fusion ProteinsTelomerase

Identifiers

PMID12368209
PMCPMC1867297
OpenAlexW168461693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.